Drug Profile
Bedaquiline - Janssen Infectious Diseases BVBA
Alternative Names: AIDS-222089; Bedaquiline fumarate; R 403323; R-207910; Sirturo; TMC-207Latest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Developer Global Alliance for TB Drug Development; Janssen Infectious Diseases BVBA; Janssen-Cilag; Johnson & Johnson; Pharmstandard
- Class Antileprotics; Antituberculars; Dimethylamines; Naphthalenes; Quinolines; Small molecules
- Mechanism of Action Adenosine triphosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Tuberculosis
- Phase III Mycobacterium avium complex infections
- Phase II Leprosy
Most Recent Events
- 09 Jan 2024 Janssen Research & Development completes a phase II trial in Leprosy (Treatment-naive) in Brazil (PO, Tablet) (NCT03384641)
- 19 Feb 2023 Efficacy and adverse events data from a phase III trial for Tuberculosis presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023 (CROI-2023)
- 08 Feb 2023 Global Alliance for TB Drug Development completes a phase III trial in Tuberculosis (Combination therapy, In adults, In adolescents, In the elderly, Treatment-resistant) in Georgia, Moldova, Russia, South Africa (PO) (NCT03086486)